The theme of the 21st National Cancer Awareness Week (April 15-April 21) is “Science against cancer, care for life”, with the subtopic “Fight against cancer, start from understanding”. At present, malignant tumor has become the first cause of death of urban residents in China, accounting for 20% of all deaths and showing a continuous growth trend. Among them, lung cancer has risen the most, by 465% in the past 30 years, and has replaced liver cancer as the disease with the highest mortality rate among malignant tumor patients. The common treatment methods in China are surgery, radiotherapy and chemotherapy. Due to the incomplete treatment of these methods, the survival time of tumor patients in China is generally about 3-6 months. What is bio-immunotherapy technology? CLS biological immunotherapy is an autologous cell therapy, specifically, the special functional cells DC and CIK mononuclear cells, which are specialized in dealing with tumor cells, are successfully separated from the peripheral blood of human body, and through the special laboratory, the cells are activated and value-added, and finally returned to the patient’s body to systematically kill tumor cells and effectively solve their metastasis and spread, which overcomes the three traditional treatment methods of surgery, radiotherapy and chemotherapy. It overcomes the disadvantages of surgery, radiotherapy and chemotherapy, which are “incomplete, easy to metastasize and have great side effects”, and is internationally recognized as the fourth new technology therapy that has the hope of completely eliminating tumor cells. What is the effect of CLS bioimmunotherapy? Bioimmunotherapy refers to a treatment method to inhibit and kill cancer cells by culturing and proliferating self-cancer cells in vitro through various biological agents and biotechnological means. As tumor infiltration leads to serious decline in patients’ quality of life, the combined application of traditional therapy and bioimmunotherapy can prevent the spread of metastasis and improve the immune resistance of the body while treating the primary lesion. According to years of follow-up and return visit of tumor patients treated with CLS, the 3-year survival rate of tumor patients is 72%, 33% for those who did not use it, and the 5-year survival rate is 67%, 22% for those who did not use it, which shows that CLS bioimmunotherapy can improve the 5-year survival rate of tumor patients nearly double! Is biologic therapy eligible for medical insurance? On April 15, 2012, the Chinese government officially enrolled the therapeutic technology biological cell immunity into medical insurance. Liaoning Provincial People’s Hospital, as a national medical insurance designated hospital, is the first to implement the medical insurance policy, and the maximum reimbursement ratio for tumor patients receiving biological therapy can reach 80%. For example, if a patient’s biological treatment costs 20,000 yuan for one course of treatment (8 times), the patient must pay the full amount in the past, but after using the medical insurance reimbursement, the individual only needs to pay 4,000 yuan (including the starting line), and the burden ratio is reduced to 80%, which is half of the money less than the original one. The hospital will settle with the provincial medical insurance center. The overall treatment cost of biotherapy is significantly lower than the cost of radiotherapy and chemotherapy. After years of clinical research, Liaoning Provincial People’s Hospital has accumulated rich clinical experience in the field of tumor biotherapy, and has established a complete tumor marker library, and has rich treatment plans for all types of clinical malignant tumors, which has been generally recognized by doctors and patients during years of clinical treatment.